On 3/30/2017, Shares of Steelcase Inc. (NYSE:SCS) closed at $16.40 in last trading day. After noting the initial trading entry at $16.60, it reached to a day’s high of $16.80 and moved to a day’s low of $16.27. The recent daily volume was 545.53 thousand as contrast to it’s an average volume of 658.71 thousand.
The last close of the Steelcase Inc. stock reflects that it traded -0.07% from its 50-day moving average of $16.41. The stock traded above +5.35% to its 200-day MA of $15.57. Furthermore, it moved lower -9.59% from its 52-week high of $18.14 and +29.44% up from $12.67, which is 52-week low of the stock.
Steelcase Inc.’s (SCS) moved with shift of -3.36% in the past week. Over the last three months, the shares of the company have changed -6.26% and performed 18.61% over the last six months. The stock currently has Monthly Volatility of 2.94% and Weekly Volatility of 2.66%.
Steelcase Inc. designs, manufactures, and distributes an integrated portfolio of furniture settings, user-centered technologies, and interior architectural products. The company operates through Americas, EMEA, and Other Category segments. Its furniture systems portfolio comprises panel-based and freestanding furniture systems; and complementary products, such as storage, tables, and ergonomic worktools. The company’s seating products include ergonomic chairs; seating for collaborative or casual settings; and specialty seating for specific vertical markets, such as healthcare and education. Its interior architectural products consist of full and partial height walls and doors. The company also manufactures and sells surface materials consisting of textiles and wall coverings to architects and designers; and ceramic steel surfaces primarily for third-party fabricators and distributors to create static whiteboards and chalkboards. In addition, it provides workplace strategy consulting, lease origination, furniture and asset management, and hosted space services. The company markets its products to corporate, government, healthcare, education, and retail customers under the Steelcase, Coalesse, Designtex, PolyVision, and Turnstone brands. It distributes its products and services through a network of independent and company-owned dealers, as well as directly to end-use customers. Steelcase Inc. was founded in 1912 and is headquartered in Grand Rapids, Michigan.
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) finalized the last transaction at value of $38.90, with a daily change of -0.71% or -0.28 points. The company maintained volume of 521.87 thousand shares. In past trading day, the stock hit the maximum price of $39.33 and touched to minimum value of $38.72. It has a market cap of $ 2.20B.
As of last trade close, the stock is trading downside -5.74% from its one year high of $41.27 and moved +148.09% upward from $15.68, which is one year low of the stock.
The stock traded above +7.82% from its 50-day moving average of $36.08. Furthermore, the stock moved up +54.01% to its 200-day MA of $ 25.26.
During the last month, Portola Pharmaceuticals, Inc.’s (PTLA) has changed 2.88% and performed 67.10% over the last 6 months. The mean rating score for this stock is at 1.90. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 3.64% in recent month and observed Weekly Volatility of 2.59%.
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.